*0012416916
*00520240830090031.0
*007ta
*008240206s2024    no a   e m    0   0 eng
*00901879nam a2200397 c 4500
*019  $bl
*020  $a9788230863060$qheftet
*035  $a(EXLNZ-47BIBSYS_NETWORK)999922337844302201
*035  $a(NO-DIMO)f015e695-1179-4c80-bf02-4c34adffc57b
*035  $a(NO-LaBS)25602983(bibid)
*035  $aoai:nb.no:pliktmonografi_000030982
*035  $aoai:nb.no:pliktmonografi_000030982
*040  $aNO-OsNB$bnob$erda
*0410 $aeng$beng$bnob
*060 4$aWL 350
*097  $aUkat
*1001 $aSzigetvari, Peter Daniel$0(NO-TrBIB)1707990468305$4aut$_325157100
*24000$aMonoamine synthesis in neurometabolic disorders affecting catecholaminergic functioning$_325157200
*24510$aMonoamine synthesis in neurometabolic disorders affecting catecholaminergic functioning :$bbiochemical mechanisms and treatment implications$cPeter Daniel Szigetvari
*264 1$a[Bergen], Norway$bUniversity of Bergen$c2024
*300  $a1 bind$billustrasjoner
*336  $atekst$0http://rdaregistry.info/termList/RDAContentType/1020$2rdaco
*337  $auformidlet$0http://rdaregistry.info/termList/RDAMediaType/1007$2rdamt
*338  $abind$0http://rdaregistry.info/termList/RDACarrierType/1049$2rdact
*502  $aAvhandling (ph.d.) - Universitetet i Bergen, 2024
*546  $aTekst på engelsk, sammendrag på engelsk og norsk
*650 2$aBrain Diseases, Metabolic$0(DNLM)D001928$_290470900
*650 2$aCatecholamines$0(DNLM)D002395$_290471000
*650 2$aPhenylalanine$0(DNLM)D010649$_290471100
*650 2$aTyrosine$0(DNLM)D014443$_84454000
*653 6$aother$_128551900
*7001 $aSzigetvari, Peter Daniel$0(NO-TrBIB)1707990468305$tMonoamine synthesis in neurometabolic disorders affecting catecholaminergic functioning$_325157100
*7102 $aUniversitetet i Bergen$0(NO-TrBIB)90063607$4dgg$4pbl$_10049500
*85640$uhttps://urn.nb.no/URN:NBN:no-nb_pliktmonografi_000030982$3Fulltekst$yNettbiblioteket$zDigital representasjon
*913  $aNorbok$bNB
*917  $ad
*999  $aoai:nb.bibsys.no:999920486627902202$b2024-02-10T01:07:05Z$z999920486627902202
^